Table 3. Association Between Different cART Exposition and LF in Patients With HIV and HIV-HCV.
| Drugs a/cART regimens | Type of drug exposure | Time of drug exposure | ||||
|---|---|---|---|---|---|---|
| Fibrosis F0-F1 (n = 119), No. (%) | Fibrosis ≥ F2 (n = 49), No. (%) | P value | Fibrosis F0-F1 (n = 119) Months, median (Q1-Q3) | Fibrosis ≥ F2 (n = 49) Months, median (Q1-Q3) | P value b | |
| DDI | 31 (26.1) | 24 (49.0) | 0.037 | 0 (0-1) | 0 (0-39) | 0.024 |
| ABC | 48 (40.3) | 31 (63.3) | 0.053 | 0 (0-22.5) | 16 (0-42) | 0.056 |
| FTC | 72 (60.5) | 26 (53.1) | 0.631 | 8 (0-31) | 10 (0-39) | 0.792 |
| D4T | 25 (21.0) | 25 (51.0) | 0.014 | 0 (0-0) | 1 (0-44) | 0.010 |
| 3TC | 88 (73.9) | 42 (85.7) | 0.292 | 45 (0-107.5) | 84 (29-121) | 0.124 |
| TDF | 79 (66.4) | 31 (63.3) | 0.916 | 14 (0-43) | 14 (0-43) | 0.916 |
| DDC | 11 (9.2) | 7 (14.3) | 0.634 | 0 (0-0) | 0 (0-0) | 0.503 |
| AZT | 71 (59.7) | 38 (77.6) | 0.124 | 20 (0-89) | 50 (2-103) | 0.203 |
| LPV/R | 33 (27.7) | 25 (51.0) | 0.037 | 0 (0-2) | 1 (0-21) | 0.027 |
| APV | 1 (0.8) | 1 (2.0) | 0.916 | 0 (0-0) | 0 (0-0) | 0.634 |
| DAR | 20 (16.8) | 6 (12.2) | 0.733 | 0 (0-0) | 0 (0-0) | 0.634 |
| ATV | 36 (30.3) | 19 (38.8) | 0.544 | 0 (0-4) | 0 (0-17) | 0.363 |
| FPV | 7 (5.9) | 11 (22.4) | 0.027 | 0 (0-0) | 0 (0-0) | 0.024 |
| IDV | 25 (21.0) | 15 (30.6) | 0.429 | 0 (0-0) | 0 (0-7) | 0.420 |
| NFV | 14 (11.8) | 13 (26.5) | 0.110 | 0 (0-0) | 0 (0-1) | 0.089 |
| SQV | 13 (10.9) | 11 (22.4) | 0.203 | 0 (0-0) | 0 (0-0) | 0.124 |
| EFV | 43 (36.1) | 18 (36.7) | 0.918 | 0 (0-22.5) | 0 (0-19) | 0.916 |
| NVP | 41 (34.5) | 13 (26.5) | 0.580 | 0 (0-8) | 0 (0-1) | 0.363 |
| T20 | 1 (0.8) | 2 (4.1) | 0.580 | 0 (0-0) | 0 (0-0) | 0.294 |
| RAL | 10 (8.4) | 9 (18.4) | 0.247 | 0 (0-0) | 0 (0-0) | 0.176 |
| MAV | 2 (1.7) | 3 (6.1) | 0.477 | 0 (0-0) | 0 (0-0) | 0.255 |
| PIs | 82 (68.9) | 41 (83.7) | 0.202 | 24 (0-57) | 60 (14-117) | 0.027 |
| NRTIs | 113 (95.0) | 47 (95.9) | 0.916 | 164 (69.5-303) | 288 (152-360) | 0.056 |
| NNRTIs | 69 (58.0) | 26 (53.1) | 0.792 | 6 (0-63) | 1 (0-37) | 0.503 |
a Abbreviations: ddI, didanosine; ABC, abacavir; FTC, emtricitabine; d4T, stavudine; 3TC, lamivudine; TDF, tenofovir; ddC, zalcitabine; AZT, zidovudine; LPV, lopinavir; APV, amprenavir; DRV, darunavir; ATV, atazanavir; FPV, fosamprenavir; IDV, indinavir; NFV, nelfinavir; SQV, saquinavir; EFV, efavirenz; NVP, nevirapine; T20, enfuvirtide; RAL, raltegravir; MVC, maraviroc; PIs, protease inhibitors; NRTIs, nucleos(t)ide-inhibitors; NNRTIs, non-nucleoside inhibitors.
b P values were adjusted using the Benjamini-Hochberg method.